ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.85
0.00%
US Tech 100
21,019.20
0.18%
S&P 500
5,999.83
0.41%
US Dollar vs CAD
1.43333
-0.04%
Bitcoin
100,761.84
-1.49%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Intrexon Corporation (XON) Share Price

Intrexon Corporation

Intrexon Corporation (XON)

NASDAQ
4.65
0.00
(0.00%)
Closed January 06 3:00PM
Delayed by 15 minutes
4.65
0.00
( 0.00% )
Pre Market: 6:00PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
4.65
Bid
4.63
Ask
4.73
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
1.157B
Previous Close
4.65
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
248,919,000
Dividend Yield
-
PE Ratio
-3.30
Earnings Per Share (EPS)
-0.39
Revenue
6.23M
Net Profit
-95.9M

About Intrexon Corporation

Intrexon is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusiv... Intrexon is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. Show more

Sector
Pharmaceutical Preparations
Industry
Coml Physical, Biologcl Resh
Website
www.dna.com
Headquarters
Glen Allen, Virginia, USA
Founded
2020

Ask ADVFN Intelligence (AI)

XON Latest News

More News

Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares PR Newswire GERMANTOWN, Md., Jan. 26, 2021 GERMANTOWN, Md., Jan. 26, 2021...

January 26 2021
PR Newswire (US)

Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference - Management will also participate in a panel discussion at the H.C. Wainwright BioConnect 2021 Conference - PR...

January 06 2021
PR Newswire (US)

Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results

Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results - Company to provide comprehensive clinical pipeline and data updates in early December - - Continues to advance healthcare...

November 09 2020
PR Newswire (US)

Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early D...

Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early December PR Newswire GERMANTOWN, Md., Nov. 2, 2020 GERMANTOWN, Md...

November 02 2020
PR Newswire (US)

Precigen Completes Series Of Transactions To Solidify Healthcare Focus

Precigen Completes Series Of Transactions To Solidify Healthcare Focus - Company on Track to Advance Next-Generation Gene & Cell Therapies - - Company Name Changes to Precigen from Intrexon...

February 03 2020
PR Newswire (US)

Triple-Gene Announces Presentation at Upcoming Biotech Showcase Investor Conference

Triple-Gene Announces Presentation at Upcoming Biotech Showcase Investor Conference - Company to Discuss First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure - PR...

January 09 2020
PR Newswire (US)

Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML)

Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML) - Patients with AML have limited treatment options for this debilitating and...

January 06 2020
PR Newswire (US)

Darling Ingredients Acquires 100% of EnviroFlight

Darling Ingredients Acquires 100% of EnviroFlight Expanding Investment in Innovative Specialty Proteins and Feed Sustainability PR Newswire IRVING, Texas, Jan. 2, 2020 IRVING, Texas, Jan. 2, 2020...

January 02 2020
PR Newswire (US)

Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen...

Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus --Concurrent asset and stock sales reduce...

January 02 2020
PR Newswire (US)

Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Trea...

Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting PR...

November 18 2019
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

XON - Frequently Asked Questions (FAQ)

What is the current Intrexon share price?
The current share price of Intrexon is US$ 4.65
How many Intrexon shares are in issue?
Intrexon has 248,919,000 shares in issue
What is the market cap of Intrexon?
The market capitalisation of Intrexon is USD 1.16B
What is the 1 year trading range for Intrexon share price?
Intrexon has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Intrexon?
The price to earnings ratio of Intrexon is -3.3
What is the cash to sales ratio of Intrexon?
The cash to sales ratio of Intrexon is 50.8
What is the reporting currency for Intrexon?
Intrexon reports financial results in USD
What is the latest annual turnover for Intrexon?
The latest annual turnover of Intrexon is USD 6.23M
What is the latest annual profit for Intrexon?
The latest annual profit of Intrexon is USD -95.9M
What is the registered address of Intrexon?
The registered address for Intrexon is 4701 COX ROAD, SUITE 285, GLEN ALLEN, VIRGINIA, 23060
What is the Intrexon website address?
The website address for Intrexon is www.dna.com
Which industry sector does Intrexon operate in?
Intrexon operates in the COML PHYSICAL, BIOLOGCL RESH sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 17.52
(0.00%)
70.95k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 71.28
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.41
(0.00%)
2.76k
AACGATA Creativity Global
US$ 0.9399
(0.00%)
56
AALAmerican Airlines Group Inc
US$ 17.52
(0.00%)
70.95k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 71.28
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.41
(0.00%)
2.76k
AACGATA Creativity Global
US$ 0.9399
(0.00%)
56
XTIAXTI Aerospace Inc
US$ 0.088
(0.00%)
678.38M
RIMEAlgorhythm Holdings Inc
US$ 0.1448
(0.00%)
190.02M
SVMHSRIVARU Holding Ltd
US$ 0.0463
(0.00%)
134.8M
CDTConduit Pharmaceuticals Inc
US$ 0.0723
(0.00%)
93.99M
CEROCERo Therapeutics Holdings Inc
US$ 0.0423
(0.00%)
74.83M

Discussion

View Full Feed
boi568 boi568 4 minutes ago
Investor understands that Anavex is not going to be applying for an accelerated decision (which is why "surrogate endpoints," i.e., biomarkers, are not relevant), but he nonetheless posted the new FDA draft guidance regarding the need for an existing second trial using such biomarkers in an effort t
AVXL
fink fink 4 minutes ago
No hes around on X.
Too many broke homeless stinking up this front door.

Accumulating till I see the Audit.
IGPK
hondaboost hondaboost 4 minutes ago
FNVWF, $0.05. O/S; 2.3 m. It'll do reverse merger with a Big Heavy EV truck Co. valued at $1 Billion soon! So,

O/S: 2.3 m, Tiny! Thin asks to $0.2.
Konaploinks Konaploinks 4 minutes ago
Yep Mr Hathaway. This little corporation is setting itself up to be the next Msft and Apple combined. With the first beautiful over 100,000 sq. ft. manufacturing facility already all set up in Bothell Washington outside Seattle, they are heads above all the rest. With 3 data centers in Maryland/DC ,
IONQ
sab63090 sab63090 4 minutes ago
Doc328
The thing that popped into my mind immediately was SICKLE CELL DISEASE and I had an investment in one such company....this is mostly for black people
AVXL
Laster Laster 5 minutes ago
Horrible price for the $20 financing. Stock will take a hit temporarily but should recover when financing closes.
JMO.
VRSSF
stockprofitter stockprofitter 5 minutes ago
Even with warrants excersized Ackmans price model is $34
FNMA
Pedro2004 Pedro2004 5 minutes ago
The company has become a scam enterprise.
ANVS
Trooperstocks Trooperstocks 5 minutes ago
$COEP “Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform” 5 New #AI Clients contract value $1.75M for our newly acquired NextGenAi Marketing Platform : https://tinyurl.com/COEP-SecuresNewAiClients #Innovation #CoeptisTherapeutics #MLM #Coeptis #Technology #AI
COEP
navycmdr navycmdr 5 minutes ago
pre-mkt - Back on the $5 by Friday BUS !

FNMA $4.55 X $4.59 - 19,636 vol

FMCC $4.43 X $4.45 - 81,170 vol

https://investorshub.advfn.com/uimage/uploads/2025/1/7/rtwdcFMCC.JPG
FMCC
deri21 deri21 5 minutes ago
$RAPH Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
https://www.globenewswire.com/news-release/2025/01/07/3005316/0/en/Raphael-Pharmaceutical-Announces-Positive-Proof-of-
RAPH
Trooperstocks Trooperstocks 5 minutes ago
$COEP “Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform” 5 New #AI Clients contract value $1.75M for our newly acquired NextGenAi Marketing Platform : https://tinyurl.com/COEP-SecuresNewAiClients #Innovation #CoeptisTherapeutics #MLM #Coeptis #Technology #AI
COEP
gp22 gp22 5 minutes ago
$MITQ: Great entry here. Micro-float "Communication Equipment" Sector has been very hot.....$MITQ the last one to rip...Strong volume developing Monday. Lets see a follow thru
MITQ
HGilS HGilS 5 minutes ago
Jour did an amazing detective job finding that we still have some fights to fight with Purdue - the only way to get OXY right now is to be bought by Purdue. Which could happen if you look at the extensive legal fights Purdue was fighting. Besides, now that Elite has Vyvanse, and a way bigger marke
OXY
Investor082 Investor082 5 minutes ago
What he is saying is don’t expect share price to appreciate much because no major institutions or big pharmas are going go inject cash anytime soon. And that NWBO will be at the mercy of market makers. So let the blame game continue post UK approval too.

As I have been saying, the st
NWBO
BottomBounce BottomBounce 5 minutes ago
Electric Vehicle and battery maker $NIO so far deploys over 3,000 battery swapping stations in China
https://autonews.gasgoo.com/new_energy/70035646.html
NIO
getmoreshares getmoreshares 5 minutes ago
or the co. website
CGAC
Double DD Double DD 6 minutes ago
Man really nice volume!! Wow
RIME
BottomBounce BottomBounce 6 minutes ago
Electric Vehicle and battery maker $NIO so far deploys over 3,000 battery swapping stations in China
https://autonews.gasgoo.com/new_energy/70035646.html
NIO
Golden Cross Golden Cross 6 minutes ago
$TORVF Richest Graphite Deposit Processed by Volt Carbon Technologies
https://www.youtube.com/watch?v=laPhABNb8nc
TORVF
deri21 deri21 6 minutes ago
$RAPH Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
https://www.globenewswire.com/news-release/2025/01/07/3005316/0/en/Raphael-Pharmaceutical-Announces-Positive-Proof-of
RAPH
marcis marcis 6 minutes ago
Dude tell us what you exposed LOL
RDAR
Gmenfan Gmenfan 7 minutes ago
Merrick Garland closes his reign of terror with a big J6 lie

By Andrea Widburg


Garland is a vile little weasel, except that weasels are cute and clever, while Garland is just a crude, mafioso-style enforcer. If I were Pam Bondi, I’d fumigate the office he used b
MartinLutherKing MartinLutherKing 7 minutes ago
It’s called revenge to the highest level of the game
RNAZ

Your Recent History

NASDAQ
XON
Intrexon
BIT
UV4KRC
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads